Breakthroughs in age-related macular degeneration (AMD) treatments have revolutionized the management of this progressive and potentially devastating eye disease. These include treatments such as ...

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

Age-related macular degeneration (AMD) is the primary cause of vision loss in people over 65, marked by abnormal changes in the macula that lead to diminished vision and distorted perception of ...

The research team from the Natural Product Drug Development Center at the Korea Institute of Science and Technology has developed a new therapeutic agent for dry Age-related macular degeneration that ...

SEOUL, South Korea — Korean scientists have developed a revolutionary eye drop treatment for dry age-related macular degeneration (AMD), potentially eliminating the need for regular eye injections ...

Macular degeneration usually refers to the age-related degenerative changes in the retina that can result in loss of central vision. It is caused by abnormal blood vessel growth (a condition ...

Tonabersat is under clinical development by Inflammx Therapeutics and currently in Phase II for Dry (Atrophic) Macular Degeneration. According to GlobalData, Phase II drugs for Dry (Atrophic) Macular ...

EB-203 is under clinical development by Eye Bio Korea and currently in Phase II for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase II drugs for Wet (Neovascular / ...

Age-related macular degeneration (AMD) is the leading cause of vision loss in individuals over 65, characterized by abnormal changes in the macular, resulting in reduced vision and distorted objects.

Age-related macular degeneration (AMD) is the leading cause of vision loss in individuals over 65, characterized by abnormal changes in the macular, resulting in reduced vision and distorted objects.